Compare Nerdwallet Inc (NRDS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.

Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.